Clinical Trial Results:
A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line treatment administered to nephrectomised patients with metastatic clear cell renal cell carcinoma.
Summary
|
|
EudraCT number |
2004-000282-35 |
Trial protocol |
CZ GB IT |
Global completion date |
24 Sep 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
08 Jul 2016
|
First version publication date |
12 Jun 2015
|
Other versions |
|
Summary report(s) |
BO17705_CS synopsis BO17705_CSR synopsis_interim analysis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.